ScholarWorks@SUNGKYUNKWAN UNIVERSITY: SHIN, DONG HYUN

Detailed Information

SHIN, DONG HYUN (신동현)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Hepatocellular carcinoma:55||hepatocellular carcinoma:24||Liver:11||Survival:10||Hepatitis B:9||Diagnosis:8||Liver transplantation:8||Magnetic resonance imaging:8||Radiofrequency ablation:6||Prognosis:6||Hepatitis B virus:6||Carcinoma:6||Chronic hepatitis B:5||Treatment outcome:5||antiviral treatment:5||liver cirrhosis:5||Treatment:5||Fatty liver:5||Transarterial chemoembolization:4||Ultrasonography:4||Liver cirrhosis:4||transient elastography:4||liver cancer:4||radiotherapy:4||Cirrhosis:4||Mortality:4||chronic hepatitis B:4||survival:4||nonalcoholic fatty liver disease:4||Acuteonchronic liver failure:3||Living donor liver transplantation:3||Gadoxetic acid:3||Hepatocellular:3||Deep learning:3||acuteonchronic liver failure:3||Alphafetoprotein:3||overall survival:3||Microvascular invasion:3||prognosis:3||Milan criteria:3||Entecavir:3||Sorafenib:3||entecavir:3||Korea:3||Chronic liver disease:3||Nonalcoholic fatty liver disease:3||hepatitis B:3||hepatitis B virus:3||hepatocellular:3||HCC:2||body mass index:2||Radiotherapy:2||Safety:2||response:2||Antiviral agents:2||chronic:2||Ablation techniques:2||safety:2||Radiation therapy:2||Cryoablation:2||Lymphoma:2||decompensation:2||deep neural networking:2||Hepatitis C virus:2||Carcinoma, hepatocellular:2||Stage:2||Key Words:2||Liver neoplasm:2||Transient elastography:2||surveillance:2||Albuminbilirubin grade:2||Alcoholic hepatitis:2||Biomarkers:2||Hepatectomy:2||tenofovir:2||Deceased donor liver transplantation:2||Surveillance:2||acute decompensation:2||Cohort:2||Proton:2||treatment:2||treatment outcome:2||fibrosis4:2||TACE:2||Lenvatinib:2||Hepatitis A:2||mHealth:2||lowlevel viremia:2||hyperthermia:2||Tyrosine kinase inhibitor:2||Toxicity:2||Outcome:2||antiviral therapy:2||Ascites:2||Recurrence:2||.:2||Antiviral Therapy:2||Response:2||radiofrequency ablation:2||Alanine aminotransferase:2||Model for EndStage Liver Disease:2||alphafetoprotein:2||recurrence:2||Hepatitis C, chronic:1||Hepatocelluar carcinoma:1||Hepatocellular Carcinoma:1||Hong Kong Liver Cancer:1||Human melanoma black45:1||Image:1||Immune Tolerant:1||Immunetolerant phase:1||Immunochemotherapy:1||Immunosuppression:1||Incidence:1||Injury:1||Insulin resistance:1||Interferongamma releasing assay:1||Intermediate stage:1||IntimaMedia Thickness:1||KASL guidelines:1||KLCSGNCC guideline:1||Kupffer cells:1||LIVER CIRRHOSIS:1||Large BCell:1||Late presentation:1||Lifestyle modification:1||Liver Cancer:1||Liver Neoplasms:1||Liver Steatosis:1||Liver cancer:1||Liver failure:1||Liver fibrosis:1||Liver function tests:1||Longterm:1||Lymphoma, follicula:1||Lynch syndrome:1||M2BPGi:1||MELDNa:1||Medication adherance:1||Metaanalysis:1||Metabolic Syndrome:1||Metabolic syndrome:1||Metabolicassociated Fatty Liver Disease:1||Microsatellite instability:1||MoRAL score:1||Model for endstage liver disease score:1||Mononucleotide markers:1||Multidetector computed tomography:1||Multidisciplinary:1||NONALCOHOLIC STEATOHEPATITIS:1||National cohort:1||Natural history:1||Neoplasm:1||Neoplasm recurrence:1||Neoplasms:1||Nomogram:1||NonB nonC:1||Nonhodgkin:1||Nonalcoholic Fatty Liver Disease:1||Nonalcoholic fatty liver disease:1||Organ failure:1||Organ transplantation:1||Overall survival:1||PAGEB grade:1||Pembrolizumab:1||Perfluorobutane:1||Perioperative care:1||Portal occlusion:1||Portal stenting:1||Portal vein invasion:1||Portal vein tumor thrombus:1||Potency:1||Prediction model:1||Predictor:1||Prevention:1||Primary biliary cholangitis:1||Primary hepatic lymphoma:1||Progression:1||Propensity score:1||Proton beam therapy:1||Pulmonary aspergillosis:1||Quantitative hepatitis B surface antigens:1||RFA:1||Radioembolization:1||Randomized controlled trials:1||Realworld practice:1||Recurrencefree survival:1||Resection:1||Return to work:1||Risk prediction model:1||Risk score:1||Rituximab:1||Scoring system:1||Screening:1||Short Physical Performance Battery:1||Signal intensity ratio:1||Spontaneous rupture:1||Statin:1||Statins:1||Stigma:1||Strategy:1||Subcentimeter:1||Surgery:1||Sustained virological response:1||Tamoxifen:1||Tenofovir:1||Tenofovir alafenamide:1||Tenofovir disoproxil fumarate:1||Trancatheter arterial chemoembolization:1||Transaminases:1||Transarterial radioembolization:1||Transmission:1||Treatment indication:1||Tumor:1||Tumor recurrence:1||Ultrasound:1||Ursodeoxycholic acid:1||Ursodeoxycholic acid response score:1||Vaccination:1||Validation:1||Varix:1||Venous intervention:1||Viral hepatitis:1||Virologic response:1||Visittovisit:1||Yttrium90:1||acetylcholine:1||achalasia:1||acute kidney injury:1||acute liver failure:1||adverse outcomes:1||age:1||alanine aminotransferase:1||albuminbilirubin grade:1||alcholic liver disease:1||alcoholic hepatitis:1||androgen receptor:1||antineoplastic hormonal drug:1||antiviral selection:1||antivirals:1||ascites:1||autologous:1||bacterial translocation:1||blood component:1||blood transfusion:1||bridge therapy:1||carcinogenesis:1||carotid atherosclerosis:1||clinically significant portal hypertension:1||complication:1||core antibody positive:1||early detection of cancer:1||efficacy:1||elderly:1||employment:1||erosive esophagitis:1||estrogen:1||exercise:1||expanded Baveno VI criteria:1||extrahepatic cancer:1||extrahepatic malignancy:1||extrahepatic metastasis:1||fibrosis:1||fibrosis4 score:1||filtration:1||handwashing:1||hepatic encephalopathy:1||hepatic fibrosis:1||hepatitis B virus (HBV):1||hepatitis B virus infection:1||hepatitis B virus reactivation:1||hepatitis C virus (HCV):1||hepatobiliary MRI:1||highfrequency intraluminal ultrasound:1||highrisk varices:1||highvolume plasma exchange:1||immune checkpoint inhibitor:1||immunomodulation:1||infection control:1||initial treatment:1||insulin resistance:1||intensitymodulated radiotherapy:1||kidney transplantation:1||lean:1||lenvatinib:1||leukocyte reduction:1||liver fibrosis:1||liver stiffness:1||liver stiffness measurement:1||liver transplantation:1||local:1||locoregional neoplasm:1||locoregional therapy:1||locoregional treatment:1||maintained virologic response:1||mean defined daily dose:1||metabolically healthy:1||microvascular invasion:1||model for endstage liver diseaseNa:1||mortality:1||muscle thickness:1||myocardial infarction:1||nonsmall cell lung cancer:1||nonalcoholic fatty liver:1||obesity:1||organ failure:1||physical activity:1||physical fitness:1||platelettowhite blood cell ratio:1||pneumatic balloon dilation:1||portal hypertension:1||protein induced by vitamin K absenceII:1||proton beam therapy:1||psychooncology:1||quality of life:1||random survival forests:1||reactivation:1||recurrences:1||regional differences:1||rehabilitation:1||relapse:1||risk factor:1||risk prediction:1||s esophagus:1||screening:1||sexual dimorphism:1||smoking:1||social stigma:1||sorafenib:1||spontaneous bacterial peritonitis:1||stage:1||stereotactic body radiotherapy:1||stomach:1||surgery:1||surgical resection:1||survival rate:1||survivorship:1||symptom:1||the aspartate aminotransferase to platelet ratio index:1||threedimensional conformal radiotherapy:1||time to progression:1||transarterial chemoembolization:1||trend:1||tumor biology:1||tumor burden:1||tumor marker:1||tumor microenvironment:1||validation:1||virologic response:1||weight reduction:1||young:1||간:1||간 종양:1||간세포암종:1||감시검사:1||광범위큰B세포림프종:1||비호지킨 림프종:1||알파태아단백:1||원발성 간 림프종:1||원인:1||초음파:1||타목시펜:1||혈종:1||Viruses:1||ANTIVIRAL THERAPY:1||AST to platelet ratio index:1||Acupuncture:1||Acute liver failure:1||Acute on chronic liver failure:1||Acuteon chronic liver failure:1||Acuteonchronic liver failure progression:1||Adenomatous polyp:1||Adjuvant immunotherapy:1||Alanine transaminase:1||Alcohol:1||Alcohol relapse:1||Alcoholrelated liver disease:1||Aminotransferase:1||Ancillary feature:1||Angiomyolipoma:1||Antiviral therapy:1||Arterial enhancement:1||Aspartate aminotransferase to platelet ratio index:1||Aspirin:1||Autoimmune hepatitis:1||BAT25:1||BAT26:1||Barcelona Clinic Liver Cancer:1||Barcelona Clinic Liver Cancer stage C:1||Barrett&apos:1||Baveno VI criteria:1||Bleeding:1||Blood vessels:1||CANCER PREVENTION:1||Cancer:1||Cancer survivors:1||Carcinoma, Hepatocellular:1||Cause:1||Cause of death:1||Cavernous transformation:1||Chemoembolization:1||Chemoprevention:1||ChildPugh classification:1||ChildPugh score:1||Chronic:1||Chronic Hepatitis B:1||Chronic Liver Disease:1||Chronic hepatitis:1||Chronic kidney disease:1||Classification:1||Clinical practice guidelines:1||Cohort study:1||Colonoscopy:1||Colorectal cancer:1||Complication:1||Computed tomography:1||Contrast:1||Contrast media:1||Controlled attenuation parameter:1||Convolutional neural network:1||Cross infection:1||Cumulative Incidence:1||Curative:1||Cytokineinduced killer cell:1||Cytomegalovirus infection:1||DIABETES MELLITUS:1||DNA:1||Diabetes:1||Diagnostic criteria:1||Diagnostic test:1||Diffuse:1||Directacting antiviral:1||Dynamic imaging:1||EPIDEMIOLOGY:1||Early recurrence:1||Education:1||Efficacy:1||Enhancement:1||Etiology:1||Exercise in cancer:1||Explosions:1||FIB4:1||Fibrosis:1||Frailty:1||GGT:1||Gastrectomy:1||Glycemic variability:1||Glycosylated hemoglobin:1||Grade:1||Guideline:1||Guidelines:1||HBV:1||HBV DNA redetection:1||HBV flare:1||HBsAg:1||HEPATITIS B:1||HEPATOCELLULAR CARCINOMA:1||HOMA2IR:1||Heart:1||Helicobacter pylori:1||Hemangioma:1||Hematoma:1||Hepatic decompensation:1||Hepatitis B Virus:1||Hepatitis B, chronic:1||Hepatitis C:1||

STATISTICS: Total View :5,228,538; Today View :425

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE